Insys Therapeutics, Inc. (NASDAQ:INSY)‘s stock had its “outperform” rating restated by Royal Bank Of Canada in a research report issued on Wednesday. They presently have a $14.00 price objective on the specialty pharmaceutical company’s stock. Royal Bank Of Canada’s target price suggests a potential upside of 78.34% from the company’s current price.

Several other equities research analysts have also issued reports on INSY. Zacks Investment Research lowered shares of Insys Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 9th. BidaskClub lowered shares of Insys Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. TheStreet lowered shares of Insys Therapeutics from a “c-” rating to a “d+” rating in a research report on Monday, August 21st. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Insys Therapeutics in a research report on Thursday, August 3rd. Finally, Piper Jaffray Companies set a $10.00 target price on shares of Insys Therapeutics and gave the company a “hold” rating in a research report on Wednesday, July 26th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $13.25.

Insys Therapeutics (NASDAQ:INSY) opened at 7.85 on Wednesday. The company’s 50-day moving average is $9.17 and its 200-day moving average is $10.97. The firm’s market capitalization is $570.66 million. Insys Therapeutics has a 52-week low of $7.55 and a 52-week high of $15.06.

Insys Therapeutics (NASDAQ:INSY) last announced its earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.12. Insys Therapeutics had a negative net margin of 9.63% and a negative return on equity of 3.02%. The business had revenue of $42.60 million during the quarter, compared to analyst estimates of $36.90 million. During the same period in the previous year, the business posted $0.13 earnings per share. Insys Therapeutics’s revenue for the quarter was down 38.4% on a year-over-year basis. Analysts forecast that Insys Therapeutics will post ($0.29) EPS for the current fiscal year.

WARNING: This story was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/10/11/insys-therapeutics-insy-outperform-rating-reaffirmed-at-royal-bank-of-canada.html.

In other Insys Therapeutics news, major shareholder John N. Kapoor Trust Dated Sept acquired 17,500 shares of the stock in a transaction dated Friday, August 11th. The stock was purchased at an average cost of $8.93 per share, for a total transaction of $156,275.00. Following the acquisition, the insider now owns 31,982 shares in the company, valued at approximately $285,599.26. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Saeed Motahari bought 5,500 shares of the firm’s stock in a transaction that occurred on Thursday, August 10th. The stock was purchased at an average cost of $8.92 per share, for a total transaction of $49,060.00. Following the completion of the purchase, the chief executive officer now owns 15,400 shares of the company’s stock, valued at $137,368. The disclosure for this purchase can be found here. Insiders own 67.90% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC purchased a new position in shares of Insys Therapeutics in the second quarter worth $138,000. Voya Investment Management LLC purchased a new position in shares of Insys Therapeutics in the second quarter worth $149,000. American International Group Inc. increased its stake in shares of Insys Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 14,462 shares of the specialty pharmaceutical company’s stock worth $152,000 after buying an additional 953 shares during the period. BNP Paribas Arbitrage SA increased its stake in shares of Insys Therapeutics by 213.2% in the second quarter. BNP Paribas Arbitrage SA now owns 13,133 shares of the specialty pharmaceutical company’s stock worth $166,000 after buying an additional 8,940 shares during the period. Finally, UBS Asset Management Americas Inc. purchased a new position in shares of Insys Therapeutics in the first quarter worth $172,000. 25.44% of the stock is currently owned by institutional investors.

Insys Therapeutics Company Profile

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Receive News & Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.